IMPALUX is a prospective, observational, multi-center platform study in adult patients with advanced (stage IIIB/IV) non-small-cell lung cancer (NSCLC) lacking actionable driver mutations (ALK, EGFR, BRAF, HER2, MET, NTRK, RET, ROS1) and with PD-L1 tumor cell expression (TPS < 50%). The study aims to elucidate the association between tumor immune/molecular features and response as well as disease course under standard-of-care immunochemotherapy. Patients provide tumor biopsies at baseline, around six weeks after initiation of immunochemotherapy, and upon suspected disease progression for molecular and immunohistochemical profiling of immune and gene expression markers. No investigational drug is administered; the design is purely observational. Secondary objectives include identifying biomarkers predictive for response and progression-free survival.
The IMPALUX study collects tumor tissue and clinical data from adults with advanced non-small cell lung cancer (NSCLC) who are undergoing immunochemotherapy. The goal is to understand whether certain immune and genetic markers in the tumor are linked to how well patients respond to therapy and how their disease progresses. Tumor biopsies are obtained before treatment, around six weeks after starting therapy, and in case of progression — and are then analyzed in the lab. This may help identify which patients benefit most from immunotherapy. Participation offers patients a contribution to research advancing personalized cancer care
